Pacira Biosciences (PCRX) reported preliminary 2024 revenue Friday of $701 million, up from $675 million a year earlier.
Analysts polled by FactSet expect $695.1 million.
The company also outlined a five-year strategy to expand its focus on musculoskeletal pain and related areas, aiming for growth by 2030.
The plan, called 5x30, includes treating more than 3 million patients annually, achieving double-digit annual revenue growth, increasing gross margins by 5 percentage points, advancing five new clinical programs and establishing five partnerships, Pacira said.
Shares of the company jumped 16% in recent Friday trading.
Price: 21.62, Change: +3.04, Percent Change: +16.36
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。